Codexis, Inc. 10-Q Summary: Quarter Ended June 30, 2010
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for Codexis, Inc., covering the three and six months ended June 30, 2010. Codexis is a developer of proprietary biocatalysts (enzymes and microbes) used to accelerate chemical reactions, primarily serving the pharmaceutical industry and the advanced biofuels sector. A significant event during this period was the company's Initial Public Offering (IPO) on April 27, 2010, which resulted in the conversion of all redeemable convertible preferred stock to common stock.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2010 | Six Months Ended June 30, 2010 | Six Months Ended June 30, 2009 |
|---|---|---|---|
| Total Revenues | $24,480 | $50,180 | $38,609 |
| Net Loss | $(3,946) | $(5,315) | $(8,951) |
| Net Loss Per Share (Basic & Diluted) | $(0.15) | $(0.36) | $(3.44) |
| Cash and Cash Equivalents (End of Period) | $51,413 | $51,413 | $28,154 |
| Working Capital | $83,713 | $83,713 | $16,397 |
| Product Gross Margin | 28% | 23% | 17% |
Liquidity and Debt: As of June 30, 2010, the company held $51.4 million in cash and cash equivalents and $48.9 million in marketable securities. Total financing obligations were $5.4 million, all classified as current liabilities. The company has an accumulated deficit of $164.9 million.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 28% for the three months ended June 30, 2010, compared to the same period in 2009. For the six-month period, revenues grew 30% to $50.2 million. This growth was driven by a 102% increase in product revenues (Q3) and a 68% increase (YTD), alongside new government grants.
- Profitability Improvement: While the company remains unprofitable, the net loss narrowed significantly. The six-month net loss decreased from $8.95 million in 2009 to $5.32 million in 2010. This improvement is largely attributed to a $3.1 million reduction in royalty fees paid to Maxygen (a related party) and improved product gross margins.
- Capital Structure: The IPO generated approximately $67.5 million in net proceeds. Consequently, the balance sheet shifted from a stockholders' deficit of $(144.8) million at year-end 2009 to positive stockholders' equity of $104.3 million at June 30, 2010.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 40% year-over-year for the quarter, primarily due to higher compensation costs (including accelerated stock-based compensation vesting post-IPO) and public company readiness costs.
Guidance, Outlook, and Risks
- Profitability Outlook: Management does not expect to achieve profitability prior to at least 2012. The company intends to continue investing heavily in research and development (R&D) to expand its biocatalyst portfolio.
- Key Dependencies: The company is heavily reliant on its collaborative research agreement with Shell Oil Products US. Shell accounted for 61% of total revenues for the six months ended June 30, 2010. The agreement allows Shell to reduce funded full-time employee equivalents (FTEs) with notice, which could materially impact future revenues.
- Intellectual Property Risks: Codexis relies on core technology licensed from Maxygen. The license agreement contains complex terms, and Maxygen retains the right to terminate the license regarding fuels if royalty obligations are breached. Additionally, the company faces risks related to the enforcement of its own patents and potential infringement claims.
- Internal Controls: The company disclosed a previously identified significant deficiency regarding its contract compliance process. While remediation efforts are underway, the company noted that failure to remediate could impact the accuracy and timeliness of financial reporting.
- Market Risks: The biofuels market is subject to regulatory changes, fluctuations in oil prices, and the feasibility of commercializing cellulosic ethanol. The pharmaceutical market faces consolidation and pricing pressures.
Investor Verification Checklist
- Shell Collaboration Terms: Verify the specific terms regarding FTE reductions and the duration of the exclusivity period with Shell, as this represents the majority of revenue.
- Maxygen License Status: Confirm the current status of royalty payments to Maxygen and ensure no breaches exist that could trigger termination of the fuel-related license.
- Product Margin Sustainability: Assess whether the improved product gross margins (23% YTD vs 17% prior year) are sustainable or driven by one-time factors like reduced inventory write-downs.
- Internal Control Remediation: Monitor the progress of remediation for the significant deficiency in contract compliance to ensure future financial reporting reliability.
- Customer Concentration: Review the top five customer list, as they accounted for 85% of revenues in the first half of 2010, creating high concentration risk.